Sodertalje, Sweden

Istvan Macsari


Average Co-Inventor Count = 7.5

ph-index = 1


Company Filing History:


Years Active: 2016-2017

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Istvan Macsari

Introduction

Istvan Macsari is a notable inventor based in Södertälje, Sweden. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that modulate gamma secretase. With a total of 2 patents to his name, his work is paving the way for advancements in the treatment of Aβ-related diseases.

Latest Patents

Istvan's latest patents include innovative compounds that have potential therapeutic applications. The first patent focuses on triazole compounds and their use as gamma secretase modulators. This invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. It also encompasses pharmaceutical compositions comprising these compounds, processes for making them, and their use as medicaments for the treatment and/or prevention of Aβ-related diseases. The second patent involves pyrimidine compounds, which similarly serve as gamma secretase modulators. This invention also details compounds of formula (I) and their pharmaceutically acceptable salts, along with related pharmaceutical compositions and processes.

Career Highlights

Istvan Macsari is currently associated with Acturum Life Science AB, where he continues to innovate in the pharmaceutical sector. His work is characterized by a strong focus on developing new therapeutic agents that can significantly impact patient care.

Collaborations

Istvan collaborates with talented professionals in his field, including Yevgeni Besidski and Ulrika Yngve. Their combined expertise enhances the research and development efforts at Acturum Life Science AB.

Conclusion

Istvan Macsari's contributions to pharmaceutical innovation are noteworthy, particularly in the realm of gamma secretase modulation. His patents reflect a commitment to advancing medical science and improving treatment options for Aβ-related diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…